Regulatory

CIRS RD Briefing 93 – New drug approvals by six major authorities 2014-2023

This R&D Briefing presents the results from the Centre for Innovation in Regulatory Science (CIRS) annual analysis of new active substance (NAS) approvals by six major regulatory agencies: the [...]

Assessing the use of risk-based approaches in four major agencies

Introduction Over the last years, several regulatory agencies have developed risk-based approaches for the regulatory assessment of marketing authorisations of New Active Substances (NASs) as strategies to efficiently use [...]

2024-07-09T15:21:30+00:00July 9th, 2024|Tags: , , |

CIRS RD Briefing 94 – Value of Reference Agency Reports in Enabling Reliance

Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was [...]

2024-06-20T09:33:23+00:00June 20th, 2024|Tags: , , |

CIRS RD Briefing 92 – Appraising the usability of public assessment reports for reliance

Regulatory reliance facilitates regulatory approvals, allows the use of resources more efficiently, and ultimately serves patients by accelerating access to quality-assured, safe, and effective medicines. The World Health Organisation [...]

2024-05-31T08:07:57+00:00May 29th, 2024|Tags: , , |

Improving development, regulatory and reimbursement frameworks for rare disease products

This multi-stakeholder workshop consisted of a series of presentation sessions and three parallel breakout discussions. Presentations explored trends in regulatory and HTA approvals of orphan products [...]

CIRS RD Briefing 91 – Approaches to Implementing Regulatory Reliance: Considerations for Agencies

This CIRS briefing delves into the increasingly pivotal role of regulatory reliance in the global pharmaceutical landscape. Reliance is defined by World Health Organization (WHO) as the act whereby [...]

Go to Top